GSWM
EPZM

Golden State Wealth Management’s Epizyme, Inc EPZM Stock Holding History

Golden State Wealth Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-500
Closed -$8K – 988
2020
Q1 		$8K Buy
+500
New +$10.7K ﹤0.01% 672

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Golden State Wealth Management's EPZM Position: Q2 2020 in Review

Golden State Wealth Management sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 500 shares — an estimated $8K sold.

Golden State Wealth Management first reported a position in EPZM in Q1 2020 and held it in 1 quarter. The position peaked at $8K in Q1 2020. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • Golden State Wealth Management reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
  • Golden State Wealth Management sold 500 Epizyme, Inc shares in Q2 2020, an estimated $8K.
  • Golden State Wealth Management first reported a position in Epizyme, Inc in Q1 2020 and held it in 1 quarter.
  • Golden State Wealth Management's Epizyme, Inc position peaked at $8K in Q1 2020.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on Golden State Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.